474 related articles for article (PubMed ID: 19102964)
1. Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome.
Tong XM; Zhang SY; Song T; Xu WH; Lin XN; Shu J; Liu L
Chin Med J (Engl); 2008 Dec; 121(23):2434-9. PubMed ID: 19102964
[TBL] [Abstract][Full Text] [Related]
2. Gonadotropin-releasing hormone agonist administration reduced vascular endothelial growth factor (VEGF), VEGF receptors, and vascular permeability of the ovaries of hyperstimulated rats.
Kitajima Y; Endo T; Manase K; Nishikawa A; Shibuya M; Kudo R
Fertil Steril; 2004 Mar; 81 Suppl 1():842-9. PubMed ID: 15019818
[TBL] [Abstract][Full Text] [Related]
3. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome.
Scotti L; Irusta G; Abramovich D; Tesone M; Parborell F
Mol Cell Endocrinol; 2011 Mar; 335(2):116-25. PubMed ID: 21238536
[TBL] [Abstract][Full Text] [Related]
4. Administration of low-dose LH induces ovulation and prevents vascular hyperpermeability and vascular endothelial growth factor expression in superovulated rats.
Gómez R; Lima I; Simón C; Pellicer A
Reproduction; 2004 Apr; 127(4):483-9. PubMed ID: 15047939
[TBL] [Abstract][Full Text] [Related]
5. Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability.
Gómez R; Simón C; Remohí J; Pellicer A
Biol Reprod; 2003 Jun; 68(6):2164-71. PubMed ID: 12606463
[TBL] [Abstract][Full Text] [Related]
6. Changes of mRNA expression of vascular endothelial growth factor, angiopoietins and their receptors during the periovulatory period in eCG/hCG-treated immature female rats.
Miyabayashi K; Shimizu T; Kawauchi C; Sasada H; Sato E
J Exp Zool A Comp Exp Biol; 2005 Jul; 303(7):590-7. PubMed ID: 15945074
[TBL] [Abstract][Full Text] [Related]
7. Prevention of the onset of ovarian hyperstimulation syndrome (OHSS) in the rat after ovulation induction with a low molecular weight agonist of the LH receptor compared with hCG and rec-LH.
van de Lagemaat R; Raafs BC; van Koppen C; Timmers CM; Mulders SM; Hanssen RG
Endocrinology; 2011 Nov; 152(11):4350-7. PubMed ID: 21896671
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical detection of transforming growth factor-alpha, epidermal growth factor, and vascular endothelial growth factor expression in hyperstimulated rat ovary.
Ozcakir HT; Giray SG; Ozbilgin MK; Uyar Y; Lacin S; Caglar H
Acta Obstet Gynecol Scand; 2005 Sep; 84(9):887-93. PubMed ID: 16097982
[TBL] [Abstract][Full Text] [Related]
9. Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5.
Kitajima Y; Endo T; Nagasawa K; Manase K; Honnma H; Baba T; Hayashi T; Chiba H; Sawada N; Saito T
Endocrinology; 2006 Feb; 147(2):694-9. PubMed ID: 16269461
[TBL] [Abstract][Full Text] [Related]
10. [The Predictive Role of Vascular Endothelial Growth Factor and Estradiol in Infertile Patients with Ovarian Hyperstimulation Syndrome].
Wang Q; Yang G; Yang C; Zhan B; Yang R
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jul; 34(3):565-7. PubMed ID: 12910723
[TBL] [Abstract][Full Text] [Related]
11. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
[TBL] [Abstract][Full Text] [Related]
12. GnRH Agonist Triggering Modulates PEDF to VEGF Ratio Inversely to hCG in Granulosa Cells.
Miller I; Chuderland D; Ron-El R; Shalgi R; Ben-Ami I
J Clin Endocrinol Metab; 2015 Nov; 100(11):E1428-36. PubMed ID: 26308290
[TBL] [Abstract][Full Text] [Related]
13. Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in an ovarian hyperstimulation syndrome (OHSS) animal model: implications for treatment of OHSS with dopamine receptor 2 agonists.
Ferrero H; García-Pascual CM; Gaytán M; Morales C; Simón C; Gaytán F; Pellicer A; Gómez R
Fertil Steril; 2014 Nov; 102(5):1468-1476.e1. PubMed ID: 25217874
[TBL] [Abstract][Full Text] [Related]
14. Expression and regulation of vascular endothelial growth factor ligands and receptors during menstruation and post-menstrual repair of human endometrium.
Punyadeera C; Thijssen VL; Tchaikovski S; Kamps R; Delvoux B; Dunselman GA; de Goeij AF; Griffioen AW; Groothuis PG
Mol Hum Reprod; 2006 Jun; 12(6):367-75. PubMed ID: 16648151
[TBL] [Abstract][Full Text] [Related]
15. Organ-specific production control of vascular endothelial growth factor in ovarian hyperstimulation syndrome-model rats.
Ishikawa K; Ohba T; Tanaka N; Iqbal M; Okamura Y; Okamura H
Endocr J; 2003 Oct; 50(5):515-25. PubMed ID: 14614207
[TBL] [Abstract][Full Text] [Related]
16. Effect of GnRH agonist and hCG treatment on VEGF, angiopoietin-2, and VE-cadherin: trying to explain the link to ovarian hyperstimulation syndrome.
Cerrillo M; Pacheco A; Rodríguez S; Gómez R; Delgado F; Pellicer A; Garcia-Velasco JA
Fertil Steril; 2011 Jun; 95(8):2517-9. PubMed ID: 21269615
[TBL] [Abstract][Full Text] [Related]
17. New insights in mechanisms for development of ovarian hyperstimulation syndrome.
Kasum M
Coll Antropol; 2010 Sep; 34(3):1139-43. PubMed ID: 20977119
[TBL] [Abstract][Full Text] [Related]
18. [Function of vascular endothelial growth factor in ovarian hyperstimulation syndrome].
Liang W; Chen S; Xing F
Zhonghua Fu Chan Ke Za Zhi; 2001 Nov; 36(11):651-3. PubMed ID: 11930687
[TBL] [Abstract][Full Text] [Related]
19. Serum vascular endothelial growth factor levels following luteal gonadotrophin-releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome.
Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
BJOG; 2014 Jun; 121(7):848-55. PubMed ID: 24621101
[TBL] [Abstract][Full Text] [Related]
20. A potential novel strategy, inhibition of vasopressin-induced VEGF secretion by relcovaptan, for decreasing the incidence of ovarian hyperstimulation syndrome in the hyperstimulated rat model.
Cenksoy C; Cenksoy PO; Erdem O; Sancak B; Gursoy R
Eur J Obstet Gynecol Reprod Biol; 2014 Mar; 174():86-90. PubMed ID: 24405730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
